ClinicalTrials.gg
CompletedNCT00391417Updated Oct 24, 2006

Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms

A Phase 3 interventional study of estradiol gel in Hot Flashes, sponsored by BioSante Pharmaceuticals. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-10-24.

Sponsored by BioSante Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
431
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.

Enrollment
7th of 13
431 · median 431
Started
2003
the only one that year
Phase 3
8 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
1 of 13
BioSante Pharmaceuticals

Among the 13 studies testing estradiol in Hot Flashes, this one is the 7th largest by enrollment, is the only one that started in 2003, is one of 8 in phase 3, and was the 5th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About estradiol

Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing estradiol in Hot Flashes as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of a topical estradiol gel for the treatment of hot flushes in postmenopausal women.

Read the detailed description

Estrogens are a group of hormones that play an important role in normal sexual and reproductive development in women. Estrogens serve many functions in the body. They stimulate oocyte maturation and endometrial growth, decrease bone resorption, initiate the development of secondary sex characteristics, maintain reproductive organs and glands, and affect the activity of the central nervous system. At menopause, the decrease in estrogen concentrations is often accompanied by vascular instability (hot flushes and night sweats), a rise in the incidence of heart disease, and an increasing rate of bone loss. Estrogen is available as an oral drug, a transdermal patch, or as a gel or lotion. Transdermal estrogen is preferable as compared to oral, since it avoids the first-pass metabolism in the liver. Since release of the WHI findings, current treatment recommendations are for the lowest effective dose for the shortest period of time to treat postmenopausal symptoms.

Comparison: Three doses of a transdermal estradiol gel as compared to placebo for the treatment of vasomotor and vulvovaginal atrophy symptoms in postmenopausal women.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • hot flush
  • hot flash
  • estrogen
  • vaginal atrophy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women
  • serum estradiol level less than or equal to 20 pg per mL
  • serum FSH greater than 40 mIU per mL

Exclusion criteria

Exclusion Criteria:

  • Pathological cancer findings on screening
  • abnormal endometrium
  • serious hepatic, renal or cardiac disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
431 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in number of daily moderate to severe hot flushes.

  2. Mean change from baseline in daily hot flush severity.

  3. Mean change from baseline in vulvovaginal atrophy symptoms.

Secondary outcomes

  1. Percent change from baseline in daily moderate to severe hot flush rates over time.

  2. Percent change from baseline in hot flush severity over time.

  3. Proportion of subjects with fifty to one hundred percent reductions in daily moderate to severe hot flushes.

  4. Proportion of subjects with fifty to one hundred percent reductions in hot flush severity

  5. Mean change from baseline in subject vaginal health self assessment over time.

  6. Mean change from baseline in physician assessment of vaginal atrophy.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007 Mar;109(3):588-96. doi: 10.1097/01.AOG.0000254160.62588.41. PubMed 17329509 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2006
First posted
Oct 24, 2006
Start
Sep 2003
Completion
Apr 2005
Last update
Oct 24, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Oct 24, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00391417
Lead sponsor
BioSante Pharmaceuticals
First posted
Oct 24, 2006
Start date
Sep 2003
Completion
Apr 2005
Last update
Oct 24, 2006
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion